MASTER CLASS for MC-IRSTC PROGRAM

AGENDA OF THE 3RD INTERNATIONAL SCIENTIFIC MEETING ON HEMATOLOGY,

ONCOLOGY, THROMBOSIS AND TRANSPLANTATION / TRANFUSION 2017
(THE 3RD ISMI-HOTTI, 2017)
GRAND SHERATON HOTEL, GANDARIA CITY, SOUTH JAKARTA

Day 1. Friday, November 24th, 2017

07.30-
REGISTRATION
08.00
TIME TOPICS MODERATORS SPEAKERS

BALLROOM 1
08.00- MASTER CLASS for MC-IRSTC
12.00 1. Internship Doctors & General practitioners (GP)
2. Residents
3. Specialists
4. Trainees
5. Subspeciaists/Consultants (IRSTC)
08.00- MC-IRSTC
08.50 THALASSEMIA MASTER CLASS (TMC) BASIC MODULE dr. Endang Windiastuti,
Hemoglobinopathy: Thalassemias & Hb variants/structural SpA (K)
TUTORIAL 3 - Session 1
08.00- 1.1.Basic principles, epidemiology, molecular diagnosis & the 1.1.dr. Iswari Setyaningsih,
08.15 use of family tree to diagnose thalassemia PhD, SpA
08.15- 1.2.Laboratory diagnosis (cytomor-phology, Hb 1.2.Dr. dr. Ina S Timan,
08.30 electrophoresis) in beta & alpha thalassemias. SpPK (K)
08.00- 1.3. Discussion dr. Endang Windiastuti, All Speakers
08.50 SpA (K)
08.50- MC-IRSTC
Dr. Diana Paramita, SpPD,
09.40 TMC BASIC MODULE
KHOM
TUTORIAL 3 - Session 2
08.50- 2.1.Management of Thalassemia major. 2.1.Dr dr Pustika Amalia,
09.05 SpA(K)
09.05- 2.2.Management of Thalassemia Intermedia (TDT & NT) & 2.2.Dr dr Tb Djumhana
09.20 Thalassemia minor. Atmakusuma, SpPD,
KHOM
09.20- 2.3.Discussion Dr. Diana Paramita, SpPD, All Speakers
09.40 KHOM
09.40-
COFFEE BREAK AND POSTER SESSIONS (IN FRONT OF BALLROOM 1)
10.00
10.00- MASTER CLASS for MC-IRSTC
12.00 1. Internship Doctors & General practitioners (GP)
2. Residents
3. Specialists
4. Trainees
5. Subspecialists/Consultants (IRSTC)
10.00- MC-IRSTC Dr. dr. Pustika Amalia, SpA
12.00 TMC BASIC MODULE (K)
TUTORIAL 3 - Session 3 and Session 4
10.00- 3.1.Iron overload/toxicity as a major complication of 3.1.Fernando Tricta, MD,
10.30 Thalassemia major & intermedia TDT & NTDT: From basic PhD
science to clinical aspects (diagnosis & treatment with iron (Brazil, Canada)
 chelating agents)

10.30- 3.2.Case study 1 & 2 : 3.2.Fernando

11.10 - How do you diagnose iron overload & organ iron toxicities? Tricta,MD,PhD
- How do you give appropriate, adequate and safe iron (Brazil, Canada)
chelating agents to patients?
11.10- 3.3.Complications of Thalassemia intermedia TDT versus NTDT 3.3.dr. Pandji Iriani Fianza,
12.00 SpPD, KHOM

FRIDAY PRAYER (AL-HIDAYAH MOSQUE, 4TH FLOOR), LUNCH BREAK (BALLROOM 2), and POSTER SESSION (IN FRONT OF
12.00
BALLROOM 1)
BALLROOM 1
13.00- MASTER CLASS for MC-IRSTC
15.00 1. Internship Doctors & General practitioners (GP)
2. Residents
3. Specialists
4. Trainees
5. Subspecialists/Consultants (IRSTC)
13.00- MC-IRSTC
14.00 TMC BASIC MODULE dr Hikari Ambara Sjakti,
Chronic anemia as a major complication of Thalassemias SpA (K)
TUTORIAL 3 - Session 5
13.00- 5.1.Chronic anemia as a major complication of Thalassemia 5.1.Dr. dr. Tenny Tjitra Sari,
13.20 major: From basic science to safe & appropiate blood SpA(K)
transfusion
13.20- 5.2.Case studies: 5.2.
14.00 Approach of anemia or low MCV until thalassemia beta a. dr. Ludi Dhyani
and alpha are diagnosed in various populations: Rahmartani, SpA
a.Case study 1- In Thalassemia major. b. dr. Anna Mira Lubis,
b.Case study 2 - In Thalassemia intermedia and Thalassemia SpPD, KHOM/ dr. Edison
minor YP Saragih, SpPD
14.00- MC-IRSTC Dr. dr. Darwin Prenggono,
15.00 TMC BASIC MODUL & CLINICAL TRANSFUSION MEDICINE SpPD, KHOM
TUTORIAL 3 - Session 6
14.00- 6.1.When and why do you use leukodepleted blood 6.1.Dr. dr. Pustika
14.20 components of PRCs in Thalassemia patients? Amalia,SpPD (K)

14.20- 6.2.When and why do you choose TC apheresis and do 6.2. Dr. dr. Tb.
14.40 therapeutic apheresis? Djumhana
Atmakusuma, SpPD,
KHOM
14.40- 6.3.Discussion Dr. dr. Darwin Prenggono, All Speakers
15.00 SpPD, KHOM
15.00 MC-IRTC
Prof. dr. Djajadiman
-16.00 HEMOPHILIA MASTER CLASS (HMC)
Gatot, SpA(K)
TUTORIAL 4 - Session 1
15.00 1.1.How do you approach patients with bleeding to determine 1.1. dr. Nadjwa Zamalek
-15.20 the causes by screening & confirmation of hemophilia Dalimoenthe,
laboratory tests SpPK(K)????
15.20 1.2.Management of acute bleeding & emergency cases in 1.2. Dr. dr. Novie Amelia
-15.40 hemophilia. Chozie, SpPA(K)
15.40 1.3.Discussion Prof. dr. Djajadiman All Speakers
-16.00 Gatot, SpA(K)
16.00- MC-IRTC dr. Indra Wijaya,SpPD
17.00 HMC
TUTORIAL 4 - Session 2
16.00- 2.1.Inhibitors of factor coagulations and transfusion 2.1. Dr. dr. Lugyanti
16.15 transmitted infections comlication in hemophilia. Sukrisman, SpPD,
KHOM

16.15- 2.2..Musculosceletal complications of hemophilia: What is the 2.2. dr. Fitri Anesterita,
16.30 role of medical rehabilitation? SpKFR

16.30- 2.3.Discussion 2.3.All Speakers

16.40
16.40- 2.4.Case study 2.4. dr. Fitri Primacakti,
17.00 SpA

17.00-
COFFEE BREAK AND POSTER SESSIONS (IN FRONT OF BALLROOM 1)
17.20
17.20 END OF DAY 1 SESSIONS OF THE 3RD ISMI-HOTTI 2017
 MASTER CLASS for MC-IRSTC PROGRAM
AGENDA OF THE 3RD INTERNATIONAL SCIENTIFIC MEETING ON HEMATOLOGY,
ONCOLOGY, THROMBOSIS AND TRANSPLANTATION / TRANFUSION 2017
(THE 3RD ISMI-HOTTI, 2017)
GRAND SHERATON HOTEL, GANDARIA CITY, SOUTH JAKARTA

Day 3. Sunday, November 26th, 2017

TIME TOPICS MODERATORS SPEAKERS

BALLROOM 1
08.00 - MASTER CLASS for MC-IRSTC
12.00 1. Internship Doctors & General practitioners (GP)
2. Residents
3. Specialists
4. Trainees
5. Subspeciaists/Consultants (IRSTC)
08.00– MC-IRSTC
09.40 “BLEEDINGS MASTER CLASS” (BMC) - PART 2 dr. Suradi Maryono, SpPD-
From basics to clinical aspects KHOM
TUTORIAL 5 - Session1 and Session 2
08.00- 1.1.Basic principle of primary, secondary and tertiary
08.20 hemostasis & required laboratory tests 1.1.-1.4.Prof. Dr I Made
1.2.Bleeding due to diseases or abormalities of primary, Bakta, SpPD, K-HOM
secondary and tertiary hemostasis
08.20– 1.3.How do you approach thrombocytopenia until isolated
08.40 thrombocytopenia (ITP) is diagnosed?
1.4.Are there any laboratory tests to confirm diagnosis? When
do we do bone marrow aspiration?
08.40– 2.1.What are the current ITP treatment? When do we use
09.10 Intravenous Immunoglobulin (IvIg) 2.1.-2.3.Dr. dr. Lugyanti
2.2.When do you use thrombopoietin receptor agonis Sukrisman, SpPD,
(eltrombophage)? KHOM
2.3.When are platelet transfusion and splenectomy indicated?
09.10– 3.Case studies
09.20
09.20- 3.1. ITP case in adult pasien 3.1.To be confirmed
09.32
09.32- 3.2 ITP case in pediatric patients 3.2.Dr. dr. Teny Tjitra Sari,
09.45 SpA(K)
09.45– COFFEE BREAK AND POSTER SESSIONS (IN FRONT OF BALLROOM 1)
10.00

BALLROOM 1

10.00– MASTER CLASS for MC-IRSTC

12.00 1. Internship Doctors & General practitioners (GP)
2. Residents
3. Specialists
4. Trainees
5. Subspeciaists/Consultants (IRSTC)
10.00 - MC-IRSTC
dr. Harlinda Harun, SpPD,
11.00 ONCOLOGY & SUPPORTIVE THERAPY in CANCERS
KHOM???
TUTORIAL 2 – PART 3
10.00 - 2.1.How is malnutrition develop in cancer patients 2.1-2.2. dr. Sugiyono
10.20 (pathogenesis of malnutrition)? Somoastro, SpPD, K-
2.2.What are the consequences of malnutrition to the patients? HOM

10.20 - 2.3.How do give enteral nutrition to cancer patients 2.3-2.5.Dr. dr. Noorwati
10.50 Sutandyo, SpPD, K-
2.4.When do the patients start with parenteral nutrition for HOM
cancer patients ?
2.5.When do we switch parenteral into enteral nutrition in
cancer patients?
10.50 - 2.6.Case discussions
11.00
10.00 -
JOIN BALLROOM 3 B SHAPHIRE & 3 C RUBY FOR LUNCH SYMPOSIUM
11.00
12.00–
LUNCH BREAK (BALLROOM 2) AND POSTER SESSIONS (IN FRONT OF BALLROOM 1)
13.00
13.00– MASTER CLASS for MC-IRSTC
17.00 1. Internship Doctors & General practitioners (GP)
2. Residents
3. Specialists
4. Trainees
5. Subspeciaists/Consultants (IRSTC)
13.00– MC-IRSCT
Dr. Djoko Heri, SpPD,
14.50 CANCER PAIN MANAGEMENT MASTER CLASS, BASIC MODULE
KHOM
TUTORIAL 6 - Session 1 and Session 2
13.00– 6.1.Pathogenesis of cancer pain
13.30 6.2.How do we assess the cancer pain and how do we use the 6.1-6.2.Dr. dr. Ikhwan
score system ? Rinaldi, SpPD, K-HOM
13.30– 6.3.When do we start with cancer pain killer and what kind of
14.00 pain killer shoud we choose?
6.4.When do we start with opioid in cancer pain ? What kind of 6.3.- 6.5.dr. Asrul Harsal,
opioid should we choose? Is it safe for patients? SpPD, K-HOM
6.5.How do we switch the opioids from one drug to another?
14.00– 6.6 Are there any other measures in cancer pain management
14.15 beside pain killer agents dr. Nadia Ayu Mulansari,
14.15- 6.7.Case discussion SPPD, KHOM
14.30
14.30- 6.8.Cancer pain in adult patients
14.45
14.45- 6.9.Cancer pain in pediatric patients dr. Hikari Ambarasjakti,
15.00 Sp.A(K)
15.00 MC-IRSCT Dr. Nyoto Widyo Astoro,
ANTI THOMBOTIC THERAPY MASTER CLASS SpPD, KHOM
TUTORIAL 7
15.00- 1. Deep vein thrombosis (DVT)
15.15
15.00- 1.1.Hemostasis & Pathogenesis of thrombosis
15.05
15.05- 1.2.Risk and trigger factors of thrombosis Dr. dr. Lugyanti Sukrisman,
15.10 SpPD, KHOM

15.10- 1.3. How do you diagnose patients with suspected DVT with
15.15 Wells score?
15.15- 1.4. Which algorithm is used to confirm DVT diagnosis?
15.20
15.20- 1.5. How do you treat acute DVT ?
15.25
15.25- 2. Pulmonary embolism (PE)
15.40
15.25- 2.1.Pulmonary embolism (PE) is an acute complication of DVT.
15.30 When do we suspect that our patients are PE? Prof Dr dr Karmel L
15.30- 2.2.When and how do we use GENEVA Score System for Tambunan, SpPD, KHOM
15.35 Suspected PE, followed wih ACCP Algorithm
15.35- 2.3.How do we treat PE ?
15.40
15.40- Classes of anti thrombotic agents: Anti coagulants (conventional
16.00 & New Anti-coagulants/ NOAC, anti platelet, thrombolytic dr Eko Adhi Pangarsa,
agents and their mechanism of actions SpPD, KHOM????
16.00- Bleeding in a major complication of anticoagulants, How do we
16.10 cope this?
16.10- What should we do if the patients on anticoagulants (NOAC) will Prof. Dr. dr. Aru W.
16.30 undergo surgery or teeth extraction? Shoud do we do bridging Sudoyo, SpPD, KHOM
therapy ?
16.30- Case studies Dr. Dwi Wahyunianto,
16.45 a. VTE in adult patients SpPD
16.45–
COFFEE BREAK AND POSTER SESSIONS (IN FRONT OF BALLROOM 1)
17.15
17.15 END OF THE 3RD ISMI-HOTTI 2017
 INTERNSHIP PROGRAM (IP) & GENERAL PRACTITIONER (GP) PROGRAM
AGENDA OF THE 3RD INTERNATIONAL SCIENTIFIC MEETING ON HEMATOLOGY, ONCOLOGY, THROMBOSIS AND
TRANSPLANTATION / TRANFUSION 2017
(THE 3RD ISMI-HOTTI, 2017)
IMERI BUILDING, LEVEL 1 (AUDITORIUM), UNIVERSITY INDONESIA, DR. CIPTO MANGUNKUSUMO NATIONAL
HOSPITAL, CENTRAL JAKARTA

Wednesday, November 22nd, 2017

A. BLOOD TRANSFUSION MASTER CLASS : 08.00 – 14.15
B. ONCOLOGY MASTER CLASS: B.1. PEDIATRIC ONCOLOGY: 14.15 – 15.15
B.2. SUPPORTIVE THERAPY IN CANCER PATIENTS: 15.15 – 16.15

07.30-
REGISTRATION
08.00
TIME TOPICS MODERATORS SPEAKERS

AUDITORIUM, LEVEL 1 - FKUI

A. BLOOD TRANSFUSION MASTER CLASS (BTMC) for:
1. Internship Doctors : Pre program
2. Internship Doctors; Post program
08.00–
3. General practitioners (GP) in the Primary Health Service
15.00
(IGP)
BLOOD TRANSFUSION MASTER CLASS
(BTMC): “Safe and appropriate use of blood trasfusion in
clinics”

IGP – BTMC, TUTORIAL 1.

08.00- Dr. dr. Ratna Sitompul,
Welcome speech form the Dean of Medical Faculty, University
08.15 SpM(K)
Indonesia
Session 1.
“Phylosophy of blood transfusion: Safe and appropriate use of
blood”
1.1, WHO (1997 – 1998) 7 key points of the appropriate use of
blood”
1.2. Flow chart of the safe and appropriate use of blood Dr dr Tb Djumhana
08.15-
Atmakusuma, SpPD,
09.15 1.3. When is blood transfusion indicated? When is blood
KHOM
transfusion contraindicated?
1.4. When do you need blood transfusion for your patients?
Does a patient with anemia, thrombocytopenia & bleeding
always need blood transfusion?
1.5. What kind of donor blood are requested?
 Session 2.
09.15-
“Blood banking”- Safe donor blood - Part 1
10.15
2.1. Flow chart of the donor blood from the donor selection
until the donor blood is released from Nlood Transfusin
Service (BTS)/ Unit Transfusi Darah (UTD) to hospital blood
bank (HBB)
2.2, a. What kind of blod componets do you have in Blood
Trasfusion Service (BTS/UTD)?
b. What kind of blood components do yu have in Hospital dr Saptuti Chunaeni
Blood Bank? MBiomed
2.3, How do you find safe blood donors? What are the
09.15-
requirements of blood donors?
10.15
2.4. How are the donor blood separated, processed and
stored ?
2.5. How many kinds of blood components can be separated
from the whole donor blood ?
2.6. What is the indications of each blood components?
2.7. What are leukodepleted blood components (packed red
cells/PRC, platelet concentrates? 2,8. How are those
leukodepleted blood components produced?
10.15- Session 3
10.30 “Blood Banking” – Safe donor blood – Part 2
3.1. What do you do with the collected donor blood to detect
the transfusion transmitted diseases (TTD)? What test is it the
most sensitive and specific one if you compare among the
available tests (rapid test ?, ELISA, Nucleic acid testing (NAT),
RT-PCR ?

3.2. How do you test the collected donor blood to determine

blood group types (ABO-Rhesus typing) in BTS / UTD and in
hospital blood bank? (slide test, tube test, gell test, magnetic
test, molecular tests?

3.3. How do you test the collected donor blood to have the
matched donor blood components for the recipients/ patients
(crossmatching between donor blood and recipeient blood) ? dr Saptuti Chunaeni
MBiomed
3.4. What is Coombs test? When and what for do we do
Coombs test?

3.5. How are the blood components released from the BTS to
hospital blood banks?

3.6. What is a cold chain system in tranfering blood

components from BTS to hospital blood bank and from
hospital blood bank to patients?
10.30- Session 4 Dr dr Tb Djumhana
11.40 “ Blood transfusion practice in hospitals” Atmakusuma, SpPD,
4.1. Flow chart of the blood transfusion practice since a doctor KHOM
prescribes / orders donor blood components for a patient, to dr Anna Mira Lubis, SpPD,
patient blood specimen collection until donor blood KHOM
components are tranfused to a patient
 4.2. How do you order / prescribe blood transfusion fo your
patients ?

4.2, How is a patient blood specimen collected?

4.3. What does the hospital blood bank do if the blood bank
receives a patient blood specimen

4.4. How are blood components transfused to patients ?

4.5. When are you transfusing blood components (packed red

cells/PRC or platelet concentrate/TC) using bedside filters to
obtain leukodepleted PRC or leukodepleted TC?

4.6. How do you use these bedside filters?

4.7. How do you prepare a patient pre transfusion and

monitor the patient during and after blood transfusion?

4.8. What are the acute and delayed bood transfusion

complications which can be developed during and after blood
transfusion?

4.9. What shoud you do if the blood transfusion complications

occur?
4.10. What should the hospital blood bank do if the blood
transfusion complications occur?

4.11. Can you prevent those acute and delayed complications?

11.40-
Case studies All Speakers
12.00
.Why and how do the patients with cancer cytotoxic dr. Nadia Ayu Mulansari,
chemotherapy develope nausea, vomiting and SpPD, KHOM
12.00- stomatitis?
12.20 .How do you treat nausea, vomiting and stomatitiis. Can those
side effects be prevented ?
Dicussion
12.20-
Lunch and Praying
13.15
13.15- “Blood transfusion in various clinical conditions”
14.45 Session 5

13.15- 5.1. Blood transfusion in obstetrical & gynaecological Dr. dr. Ali Sungkar,
13.45 bleedings” SpOG(K)
13.05-
13.15 Discussion
13.45 5.2. Blood transfusion in thrombocytopenia (DHF, ITP, aplastic Dr. dr. Andhika Rachman,
14.05 anemia, prior invasive procedures SpPD, KHOM
14.05-
14.15 Discussion
14.15- 5.1. Blood transfusion in hematemesis – melena Dr. dr. Ari Fachrial, SpPD,
14.35 KGEH
14.35-
14.45 Discussion
 Note: Blood transfusion in Thalassemias and Hemophilia will be available on Friday November 2017 at the 3rd ISMI
HOTTI 2017 (in Grand Sheraton Hotel , Gandaria City, Kebayoran Baru)
IGP
ONCOLOGY & SUPPORTIVE CARE in CANCERS
TUTORIAL 2 – PART I and II
14.45- B. 1. PEDIATRIC ONCOLOGY SPECIAL CLASS (PART 1)
15.45
14.45- 1.1. Cancers in pediatric patients; How should we do to have Prof. dr. Djajadiman Gatot,
15.05 early diagnosis? SpPD, KHO(K)
15.05- Discussion
15.15
15.15- 1.2. Supportive therapy and oncology emergency in pediatric Dr.Endang
15.35 cacer patients: What should we know and do? Windiastuti,SpA(K)
15.35- Discussion
15.45
15.45- B.2. SUPPORTIVE THERAPY IN CANCER PATIENTS
16.15
15.45- 2.1.Cancer systemic therapy: Cytotoxic chemotherapy. Prof. Dr. dr. A. Harryanto
16.05- Targeted therapy, Hormaonal therapy, Biologicl therapy: Reksodiputro, SpPD,
16.05- Classes & mechanism of actions KHOM
16.15 2.2.Adverse events and organ / system toxicities, and WHO
grade of toxicities criteria)
2.3.Discussion
16.15 Coffee break and End of Sessions